OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based mostly in San Francisco that desires people to dwell 10 years longer than what it calls a wholesome human lifespan.
Altman beforehand supplied Retro Biosciences’ whole seed spherical of $180 million. Now, the startup is elevating a $1 billion Series A that Altman is becoming a member of, the Financial Times experiences.
Retro Biosciences, which says it plans to launch trials for medication concentrating on illnesses like Alzheimer’s, just lately educated a mannequin with OpenAI to show common cells into stem cells.
CEO Joe Betts-LaCroix instructed the FT he desires to maneuver quick by discovering and creating a drug “in the 2020s.”
The startup joins different main billionaire-backed longevity efforts, together with Altos Labs, which launched with $three billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by each Bezos and Peter Thiel.
